Program
atirmociclib
Also written as “PF-07220060 + PF-07104091 combination dose escalation”, “PF-07220060” and “Atirmociclib”.
In Pfizer’s pipeline, CDK4 inhibitor
. Its studies are mostly in Breast Neoplasms · Liposarcoma · Hepatic Insufficiency, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 147 open or running | phase 3since Dec 11, 2024 | Sep 15, 2020 | Feb 26, 2027phase 2 · NCT05262400 |
| AstraZenecaits history only | 11 open or running | phase 2since Feb 16, 2026 | Feb 16, 2026 | Dec 28, 2027phase 2 · NCT07427394 |
| Hoffmann-La Rocheits history only | 11 open or running | phase 2since Jan 30, 2018 | Jan 30, 2018 | Sep 30, 2030phase 2 · NCT03424005 |
| Olema Pharmaceuticals | 11 open or running | phase 1since Aug 16, 2022 | Aug 16, 2022 | Dec 31, 2027phase 1 · NCT05508906 |
- Named in Pfizer’s own pipeline as
atirmociclib PF-07220060
, phase 3, as of Nov 3, 2026 (source).
Also a collaborator on its studies: Gilead Sciences, Arvinas Estrogen Receptor and Novartis.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Olema Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 16, 2022First study: phase 1 study in Breast NeoplasmsFirst studyNCT05508906 · 190 enrolled · United States, Australia
- Aug 11, 2024Named atirmociclibINNProposed as its International Nonproprietary Name in WHO's List 131 · before, PF-07220060
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT05508906
TargetBeta
“CDK4 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential antineoplastic activity. Upon administration, atirmociclib selectively inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase tran…”NCIt, read by Claude
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), ”NCIt, by rule
Other programs on CDK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| HRS-6209 | Jiangsu HengRui Medicine | phase 3 | 7 |
| CDK4 Inhibitor BGB-43395rule | BeOne Medicines | phase 3 | 4 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| TSL2109rule | China Resources Pharmaceutical Group | phase 1 | 1 |
Studies
The one study Olema Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05508906Breast Neoplasms · United States, Australia | 1 | Active, not recruiting | Dec 31, 2027 | 190 |
How it is read
Names in the registry
- “PF-07220060 + PF-07104091 combination dose escalation”, 8 entries
- “PF-07220060”, 7 entries
- “Atirmociclib”, 5 entries
- “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
- “Single dose of PF-07220060 as first Tablet Formulation”, 2 entries
Codes read as this program: PF07220060.
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Liposarcoma, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.